Research at the Novo Nordisk Oxford Research Center (Photo: Novo Nordisk)
BAGSVæRD – First the stock market course has been lubricated, now shooting Star Novo Nordisk also had to be the title “The most valuable company in Europe” SAP. The Danish pharmaceutical giant is in hard competition with its delegates like Wegovy. Does the Annual General Meeting bring a new spirit of optimism?
A hangover followed on the stock exchange, around 50 percent has lost around 50 percent since the all-time high in June 2024, now costs 503.60 Danish crowns (around $ 73-yesterday, 1:50 p.m. CEZ). The B shares (with simple voting rights) note on the Copenhagen stock exchange, so-called ADRs are traded in New York.
+++ Annual General Meeting by Novo Nordisk A/S +++
On Thursday March 27, 2025, the general meeting of Novo Nordisk will start at 2 p.m. (CET). The event is carried out hybrid, shareholders can choose between presence and online participation. In addition, the general meeting is Translated live via webcast.
The downward trend could also Numbers of the 4th quarter of 2024 Do not break even though they were better than expected. The net profit climbed 29 percent to 28.23 billion Danish crowns (around $ 4 billion) in the annual comparison, sales to 85.68 billion (plus 30 percent).
Positive for shareholders: The dividend increases that the general meeting is said to decide another 7.90 Danish crowns (DKK) per A or B share. As a result, the distribution for 2024 including intermediate dividend increases to 11.40 DKK. Growth has been annually since 2015 an average of about 16 percent.
Hope for the Wegovy successor-deal with United Laboratories
But the markets look ahead and have most recently weak study data the mood in the future weight loss drug Cagrisema. It combines the Wegovy active ingredient with another factor. Investors hope for signals that Cagrisema will come to the road to success.
The Danes have one step forward Made with a China deal: Novo Nordisk has acquired the rights to a weight loss ingredient from United Laboratories. This uses 3 different hormones called GLP-1, Gip and Glukagon, and is therefore also called “triple G”.
Eli Lilly also relies on China – race for the weight loss pill
Meanwhile, the struggle for the obesity market has flared up-especially Eli Lilly has good cards. As well as Novo Nordisk, the Americans cooperate with Chinese companies that develop new active ingredients. And a tight race runs in the competition for the first weight loss pill.
“We actually believe that we can compete with a tablet treatment on the US market before Lilly comes onto the market,” said Lars Fruergaard Jørgensen recently on cnbc.com. The oral drug should be available in 2026. But Eli Lilly also plans an approval in early 2026.
Locations in the USA are created – forecast by Novo Nordisk for 2025
In order to serve the increasing demand for Ozempic and Co. New works in the United Statesthe most important market for weight loss injections. Despite the risks of Trump’s customs policy, CEO Jørgensen sees Novo Nordisk well for the upcoming US business.
Growing competition and price pressure in obesity and diabetes preparations are also reflected In the forecasts for 2025 Against: The Danish company expects sales growth of 16 to 24 percent – Novo Nordisk had issued 18 to 26 percent as a target span for 2024.
Agenda of the meeting – proposal of the critical shareholders
In addition to the use of the profit Do the shareholders today too about the occupation of the board of directors (comparable to a supervisory board), its remuneration and a program for the share buyback. The authorization to increase capital should be extended.
A point of conflict on the agenda: The association of critical shareholders demands that Novo Nordisk are committed to standards for working conditions on construction sites of the company, such as a obligation to contract. Management rejects flat -rate requirements that the countries are too different.
Disclaimer:
All information without guarantee for completeness, correctness and topicality. The text does not represent a trade recommendation or investment advice.